71 reports of this reaction
1.3% of all CARVEDILOL PHOSPHATE reports
#18 most reported adverse reaction
MYOCARDIAL INFARCTION is the #18 most commonly reported adverse reaction for CARVEDILOL PHOSPHATE, manufactured by Waylis Therapeutics LLC. There are 71 FDA adverse event reports linking CARVEDILOL PHOSPHATE to MYOCARDIAL INFARCTION. This represents approximately 1.3% of all 5,587 adverse event reports for this drug.
Patients taking CARVEDILOL PHOSPHATE who experience myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYOCARDIAL INFARCTION is a less commonly reported adverse event for CARVEDILOL PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to myocardial infarction, the following adverse reactions have been reported for CARVEDILOL PHOSPHATE:
The following drugs have also been linked to myocardial infarction in FDA adverse event reports:
MYOCARDIAL INFARCTION has been reported as an adverse event in 71 FDA reports for CARVEDILOL PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYOCARDIAL INFARCTION accounts for approximately 1.3% of all adverse event reports for CARVEDILOL PHOSPHATE, making it a notable side effect.
If you experience myocardial infarction while taking CARVEDILOL PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.